Related Experiment Videos
Immunological tolerance as an adjunct to allogeneic tissue grafting
1Division of Transplant Immunology, Department of Surgery, University of Alabama, Birmingham, Alabama, USA.
Microsurgery
|January 11, 2001
Summary
Composite tissue allografts show exciting early results. Novel immune tolerance induction using CD3-immunotoxin (CD3-IT) and deoxyspergualin (DSG) offers a promising, minimally toxic approach for future transplantation research.
Area of Science:
- Transplantation immunology
- Regenerative medicine
Background:
- Composite tissue allografts (CTA) represent a unique and evolving area within transplantation.
- Early experimental and recent clinical results highlight the potential of CTA.
- Previous strategies relied on conventional immunosuppression for allografting.
Purpose of the Study:
- To review the progress and potential of composite tissue allografts.
- To introduce a novel immune tolerance induction strategy for CTA.
Main Methods:
- Review of experimental and clinical composite tissue allograft literature.
- Proposal of immune tolerance induction using CD3-immunotoxin (CD3-IT) and deoxyspergualin (DSG).
Main Results:
- Composite tissue allografts have demonstrated exciting early clinical outcomes.
- CD3-immunotoxin (CD3-IT) and deoxyspergualin (DSG) offer a potentially effective and minimally toxic immune tolerance induction method.
Conclusions:
- Composite tissue allografts are a rapidly growing field with significant potential.
- The proposed immune tolerance induction strategy using CD3-IT and DSG could benefit the field by enhancing efficacy and reducing toxicity.